Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Jan 11, 2016 6:34pm
203 Views
Post# 24448036

RE:RE:RE:RE:looks like

RE:RE:RE:RE:looks like I can't advise you on what to do.  Personally, I am holding my NOX shares and will accept the Oban shares.  Come March, subject to shareholder approval on both sides, your NioGold shares will be converted to Oban shares at a rate of 0.4167 - your brokerage should automatically do this for you unless you sell your NOX shares before then.  If you have 100,000 shares of NOX at that time, as an example, you will receive 41,670 shares of Oban.

Bottom line - if you believe that Oban will do well over the medium or long term (depends on your investment time horizon), hold your shares.  Otherwise, sell them now or in the near future (NOX shares should fluctuate in and around the current share price until March; note that if another suitor comes into the mix between now and then, NOX shares could be bid up as a result).

Niogold and Oban share a common stakeholder - Osisko Royalties.  The people behind Osisko are smart and savvy - they're not dummies.  Oskisko will very much be behind Oban and it's expected success on a go-forward basis.  Oban will have several very exciting properties (including Marban), $70MM or thereabouts in cash (very important in today's dreary mining environment), and some very capable and ambitious people.  The choice is yours. 

- MM

<< Previous
Bullboard Posts
Next >>